Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer

H. Date, K. Kiura, H. Ueoka, M. Tabata, M. Aoe, A. Andou, T. Shibayama, N. Shimizu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and irinotecan was feasible and could improve the treatment outcome for patients with pathological N2 non-small cell lung cancer. Fifteen patients with stage IIIA non-small cell lung cancer having mediastinal lymph node metastases proved by mediastinoscopy were eligible. Both cisplatin (60 mg m-2) and irinotecan (50 mg m-2) were given on days 1 and 8. Patients received two cycles of chemotherapy after 3-4 weeks interval. Induction was followed by surgical resection in 4-6 weeks. Patients who had documented tumour regression after preoperative chemotherapy received two additional cycles of chemotherapy and other patients received radiotherapy postoperatively. After the induction chemotherapy, the objective response rate was 73%. All the 15 patients received surgical resection and complete resection was achieved in 11 (73%) patients. There was no operation-related death and one death due to radiation pneumonitis during postoperative radiotherapy. The median time from entry to final analysis was 46.5 months, ranging from 22 to 68 months. The 5-year survival rate was 40% for all the 15 patients and it was 55% for the 11 patients who underwent complete resection. We conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with low morbidity and high respectability.

Original languageEnglish
Pages (from-to)530-533
Number of pages4
JournalBritish Journal of Cancer
Volume86
Issue number4
DOIs
Publication statusPublished - Feb 12 2002

Keywords

  • Cisplatin
  • Induction chemotherapy
  • Irinotecan
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N<sub>2</sub> non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this